TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26408647

Group type: EXPERIMENTAL
Intervention: Working while seated
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Working while standing
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Working while walking at low intensity
Number of subjects: 45
Study: 24562504

Group type: EXPERIMENTAL
Intervention: Postpartum IPV (emerged and repeated)
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Dissipated postpartum IPV
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Postpartum IPV prevalence
Number of subjects: 734
Study: 23018351

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 11
Study: 20496820

Group type: EXPERIMENTAL
Intervention: Bilateral injection of 20 units of botulinum toxin into each side of the internal anal sphincter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Posterior injection of 25 units of botulinum toxin into the midline posteriorly
Number of subjects: 40
Study: 17279491

Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-mesh repair
Number of subjects: 300
Study: 16218514

Group type: EXPERIMENTAL
Intervention: Xylometazoline (0.1%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (120 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Neither sympathicomimetic
Number of subjects: 20
Study: 12003052

Group type: EXPERIMENTAL
Intervention: Electronic SF-36
Number of subjects: 115

Group type: COMPARATOR
Intervention: Paper SF-36
Number of subjects: 115
Study: 10436448

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) therapy, 40 mg enoxaparin every 12 hours for 7 days, then 40 mg once daily for 3 months
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oral anticoagulant therapy (coumarin), standard unfractionated heparin followed by coumarin for 3 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) therapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Oral anticoagulant therapy (coumarin)
Number of subjects: 165
Study: 8786960

Group type: EXPERIMENTAL
Intervention: 200-mg tablets
Number of subjects: 16

Group type: COMPARATOR
Intervention: 400-mg suspension
Number of subjects: 16
Study: 2081489

Group type: EXPERIMENTAL
Intervention: nabumetone 1 g at night
Number of subjects: 243

Group type: COMPARATOR
Intervention: slow release diclofenac 100 mg at night
Number of subjects: 243
Study: 656778

Group type: EXPERIMENTAL
Intervention: Weight reduction by diet or jejunoileal shunt
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Jejunoileal shunt
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 70
Study: 31907645

Group type: EXPERIMENTAL
Intervention: QL1101 (3 mg/kg, intravenously)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Avastin® (3 mg/kg, intravenously)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: QL1101
Number of subjects: 82

Group type: COMPARATOR
Intervention: Avastin®
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: QL1101 and Avastin®
Number of subjects: 82
Study: 30638903

Group type: EXPERIMENTAL
Intervention: Online self-management program
Number of subjects: 49
Study: 28099439

Group type: EXPERIMENTAL
Intervention: Single NSE measurement at 48 hours
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Combination of all three NSE measurements
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Easily applicable combinations of serial NSE measurements
Number of subjects: 685
Study: 25869385

Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, vincristine, and prednisone (BCCA cohort)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (PRIMA trial)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Rituximab maintenance (PRIMA trial)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Observation (PRIMA trial)
Number of subjects: 581
Study: 23110683

Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 35
Study: 21884871

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg twice daily for the first day, followed by 0.5 mg twice daily for patients ≥70 kg; halved doses for patients <70 kg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 19078934

Group type: EXPERIMENTAL
Intervention: Storytelling (ST)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Risk Tool (RT)
Number of subjects: 78
Study: 16919479

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16137049

Group type: EXPERIMENTAL
Intervention: UTI 5000 U/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: NS 100 ml (Control)
Number of subjects: 30
Study: 11079282

Group type: EXPERIMENTAL
Intervention: Oxandrolone 10 mg twice/day for a maximum of 28 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10178676

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma Processing (PP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erythropheresis
Number of subjects: 50
Study: 7871058

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ritanserin (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ritanserin (5 mg) + d-fenfluramine (30 mg)
Number of subjects: 12
Study: 3527626

Group type: EXPERIMENTAL
Intervention: Careful dietary adherence and weight reduction
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Poor dietary adherence and persistent obesity
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Intensive diet therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Insulin responses
Number of subjects: 107
Study: 30875481

Group type: EXPERIMENTAL
Intervention: High-resistance-low-aerobic exercise (Re)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-resistance-high-aerobic exercise (rE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-resistance-low-aerobic exercise (re)
Number of subjects: 100
Study: 29085969

Group type: EXPERIMENTAL
Intervention: Formula feeding and multivitamin supplementation (vitamins A, C, D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Family history of urinary tract stones
Number of subjects: 120

Group type: COMPARATOR
Intervention: ApaI and FokI VDR gene polymorphisms
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CA genotype of ApaI polymorphism
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: C allele of ApaI polymorphism
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypercalciuria
Number of subjects: 120
Study: 26792776

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) on the patellar tendon
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (HRV recorded for 10 min at rest and during exhaustive US examination)
Number of subjects: 22
Study: 24673716

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine with short-term intensified EC-MPS dosing (2160 mg/day to week 6, 1440 mg/day thereafter) and corticosteroids
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard-dose cyclosporine with standard EC-MPS dosing (1440 mg/day) and corticosteroids
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine with short-term intensified EC-MPS dosing
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard-dose cyclosporine with standard EC-MPS dosing
Number of subjects: 180
Study: 22469884

Group type: EXPERIMENTAL
Intervention: Micafungin (50 mg/day i.v.)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Itraconazole (5 mg/kg/day p.o.)
Number of subjects: 287
Study: 21336020

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL) using video
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional live lecture
Number of subjects: 44
Study: 18614570

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib sodium (0.3, 1, and 3 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 0
Study: 16086613

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11808825

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg oral dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 2.5 to 10 mg tid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine multiple dosing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 5 mg tid in elderly subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine in subjects with mild hepatic insufficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine in males and females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine dosing recommendations
Number of subjects: 0
Study: 10428307

Group type: EXPERIMENTAL
Intervention: Isoflavonoid supplement (55 mg daily)
Number of subjects: 59
Study: 7767419

Group type: EXPERIMENTAL
Intervention: General ultrasound screening
Number of subjects: 11925

Group type: COMPARATOR
Intervention: Selective ultrasound screening
Number of subjects: 11925

Group type: COMPARATOR
Intervention: No ultrasound screening
Number of subjects: 11925
Study: 2258157

Group type: EXPERIMENTAL
Intervention: Propranolol (twice daily at a dose reducing heart rate by 25%)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (intravariceal and extravariceal injections of Polidocanol)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (vitamin K orally)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Propranolol vs. Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Propranolol vs. Sclerotherapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sclerotherapy vs. Placebo
Number of subjects: 126
Study: 7026693

Group type: EXPERIMENTAL
Intervention: Reference Escherichia coli endotoxin (0.1-0.5 ng/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phthalylated reference endotoxin (up to 1,000 ng/kg)
Number of subjects: 0
Study: 31775407

Group type: EXPERIMENTAL
Intervention: Transgrade technique for DRG stimulation
Number of subjects: 39
Study: 28410865

Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg intravenously every 2 weeks (TBP)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Nivolumab 3mg/kg intravenously every 2 weeks (NTBP)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Nivolumab (TBP)
Number of subjects: 406
Study: 25886635

Group type: EXPERIMENTAL
Intervention: Tokishigyakukagoshuyushokyoto (TJ‐38)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 23746562

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine and caffeine (400 mg/d PS and 100 mg/d caffeine) for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 21283958

Group type: EXPERIMENTAL
Intervention: Dermabond™
Number of subjects: 49

Group type: COMPARATOR
Intervention: Steri-Strip™
Number of subjects: 49
Study: 19341846

Group type: EXPERIMENTAL
Intervention: 10 mcg ethinyl estradiol (EE) daily during the hormone-free interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo during the hormone-free interval
Number of subjects: 0
Study: 17445751

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice a day
Number of subjects: 38
Study: 15117727

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 28
Study: 11341473

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (Dysport® 500 to 1500U or Botox® 100 to 300U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity or electrical stimulation of the injected muscles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 0
Study: 9118978

Group type: EXPERIMENTAL
Intervention: Naloxone (N; 1.2 mg; 3 ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (P; 0.9% NaCl saline; 3 ml)
Number of subjects: 8
Study: 8158817

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 40119

Group type: COMPARATOR
Intervention: Control (Hepatitis B vaccine)
Number of subjects: 40119
Study: 3341259

Group type: EXPERIMENTAL
Intervention: Nut meals (walnuts, almonds, peanuts, hazelnuts)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Bread meals
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Coconut
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (50 mg) with Brazil nuts and peanuts
Number of subjects: 137
Study: 30157771

Group type: EXPERIMENTAL
Intervention: auditive distraction
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: visual distraction
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: combination distraction
Number of subjects: 206

Group type: COMPARATOR
Intervention: control group (no distraction)
Number of subjects: 206
Study: 26796612

Group type: EXPERIMENTAL
Intervention: Neostigmine-atropine combination (Group N, n = 45)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sugammadex (Group S, n = 45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 90
Study: 25577909

Group type: EXPERIMENTAL
Intervention: Comprehensive traditional Chinese medicine therapy including passive exercise training (0-2 weeks), transition to active exercise training (3-4 weeks), and active exercise training (5-12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group received past procedure therapy
Number of subjects: 32
Study: 23109689

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin in patients with squamous tumors
Number of subjects: 239
Study: 20609640

Group type: EXPERIMENTAL
Intervention: JAPAN arm (EES implantation)
Number of subjects: 183
Study: 18691879

Group type: EXPERIMENTAL
Intervention: Cisplatin 75mg/m(2) plus Paclitaxel 175mg/m(2) plus Doxorubicin 40mg/m(2)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Carboplatin 7 AUC plus Paclitaxel 175mg/m(2)
Number of subjects: 451
Study: 15975103

Group type: EXPERIMENTAL
Intervention: Perindopril/indapamide (2.0/0.625 mg daily, increasing to 4.0/1.25 mg daily after 3 months)
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Intensive gliclazide MR-based glucose control aiming for HbA1c of 6.5% or lower
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Matching placebo for perindopril/indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Local standard therapy for glucose control
Number of subjects: 11140
Study: 14703409

Group type: EXPERIMENTAL
Intervention: SBN‐1 injection at 1 x 10(12)VP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SBN‐1 injection (all doses)
Number of subjects: 12
Study: 10350103

Group type: EXPERIMENTAL
Intervention: Captopril (CTP) 12.5 mg every 8 hours orally, from 24 hours before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no captopril)
Number of subjects: 30
Study: 8543204

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: No autologous platelet concentrate (control group)
Number of subjects: 40
Study: 2139284

Group type: EXPERIMENTAL
Intervention: 20 micrograms recombinant DNA hepatitis B vaccine (YDV)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 40 micrograms recombinant DNA hepatitis B vaccine (YDV)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Historical control group (not specified in detail)
Number of subjects: 278
Study: 7030988

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied once daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied three times daily
Number of subjects: 343
Study: 31541768

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet 20,000 Japanese Allergy Unit
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT tablet 10,000 Japanese Allergy Unit
Number of subjects: 826

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study: 31309232

Group type: EXPERIMENTAL
Intervention: Genistein 40 mg/kg
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Genistein 400 mg/kg
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Genistein (both doses)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control (0 mg/kg Genistein)
Number of subjects: 720
Study: 28139112

Group type: EXPERIMENTAL
Intervention: Self-myofascial release program for twenty weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 26758073

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 41

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 41
Study: 25064038

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) exercise training
Number of subjects: 0
Study: 21997802

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 39
Study: 19357315

Group type: EXPERIMENTAL
Intervention: Social cognitive theory‐based intervention (written materials and 5 weekly, 20‐ to 30‐min telephone counseling sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (written materials only)
Number of subjects: 59
Study: 17972459

Group type: EXPERIMENTAL
Intervention: S100beta
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation between S100beta and Mg
Number of subjects: 20
Study: 15614598

Group type: EXPERIMENTAL
Intervention: Hip protector use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11764425

Group type: EXPERIMENTAL
Intervention: Foot sole pump (A-V Impulse System)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study: 9440565

Group type: COMPARATOR
Intervention: Inhaled formoterol (FM), 24 microg bid, and placebo tablets (PL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (FM), 24 microg bid, and oral prednisolone (PRED), 15 mg daily
Number of subjects: 11
Study: 8127991

Group type: EXPERIMENTAL
Intervention: Original Oucher
Number of subjects: 79

Group type: COMPARATOR
Intervention: Reduced-size Oucher
Number of subjects: 79
Study: 2672061

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 772979

Group type: EXPERIMENTAL
Intervention: Tetraolean
Number of subjects: 1672

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 1672
Study: 31647011

Group type: EXPERIMENTAL
Intervention: Oncokompas alongside care as usual
Number of subjects: 136

Group type: COMPARATOR
Intervention: Care as usual (waiting list control group)
Number of subjects: 136
Study: 28479368

Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin (PC) induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 cycles of PC (JMDB trial)
Number of subjects: 0
Study: 25956613

Group type: COMPARATOR
Intervention: Fenofibrate 300 mg daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fenofibrate 300 mg daily plus pentoxifylline 1200 mg/day in three divided doses for 24 weeks
Number of subjects: 90
Study: 22543064

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (PCV) with tidal volume (Vt) of 8 mL•kg(‐1) and PEEP of 0 cm H(2)O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increasing PEEP from 0 to 5 cm H(2)O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increasing tidal volume (Vt)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VDSCM including flow-dependent parameter
Number of subjects: 15
Study: 21261438

Group type: EXPERIMENTAL
Intervention: High-dissonance program
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Low-dissonance program
Number of subjects: 124

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 124
Study: 19430275

Group type: EXPERIMENTAL
Intervention: Telemedicine consultations
Number of subjects: 1

Group type: COMPARATOR
Intervention: Telephone-only consultations
Number of subjects: 1
Study: 16736620

Group type: EXPERIMENTAL
Intervention: Three-point relief-tension suspension technique (Group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 82
Study: 15107217

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 70
Study: 11083648

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg i.v. every 12 h)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin (2 g i.v. every 6 h)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg orally every 12 h)
Number of subjects: 826

Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin (500 mg orally every 6 h)
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 826

Group type: COMPARATOR
Intervention: Oxacillin-dicloxacillin
Number of subjects: 826
Study: 9543224

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (900 mg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 40
Study: 1298571

Group type: EXPERIMENTAL
Intervention: Shower-based oral hygiene system (SBOHS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Manual toothbrushing
Number of subjects: 84

Group type: COMPARATOR
Intervention: Electric toothbrushing
Number of subjects: 84
Study: 2420603

Group type: EXPERIMENTAL
Intervention: Combination of cisplatin, vinblastine and bleomycin followed by intravenous cyclophosphamide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (consolidation regimen)
Number of subjects: 36
Study: 31134600

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation and auricular acupressure for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0